Pfizer and Eli Lilly last week reported their experimental pain drug tanezumab increased rates of osteoarthritis and other skeletal side effects in a Phase 3 trial that showed only limited pain-relief benefit when compared to non-steroidal anti-inflammatory drugs, or NSAIDs.
Copyright © 2019,